N(6)-(1-Carboxyethyl)Lysine.
Research-backed amino acid with potential health benefits. Advanced glycation end product formed when proteins react with sugars.
Reviewed March 2026
- Category
- Amino acid
What N(6)-(1-Carboxyethyl)Lysine is, and what it does.
- Does it work
- Something to minimize through diet and blood sugar control. Not a supplement.
- How much to take
- The band on record is 100mg to 300mg a day, though nobody takes this on purpose. It forms inside you and in cooked food, and the sold material is a measuring standard.
- Time to feel it
- There is no onset to describe. It accumulates slowly on long-lived proteins, and what you read is a laboratory measurement rather than a sensation.
- The first dose
- Nothing shifts in a day. A cooked meal adds a little, some is absorbed and some passes through, and this is chemistry you measure rather than feel.
- With regular use
- Across months and years it builds on proteins that turn over slowly, which is exactly why researchers use it as a running record of dicarbonyl exposure.
- How well tolerated
- As a laboratory standard it is not intended for eating, and human intake data at supplemental amounts has not been collected. Talk to your doctor about anything you take.
- How it feels
- There is no subjective experience. It reads out on a mass spectrometer, not in how your day goes.
- The overlooked benefit
- The nutrients paired with it, like thiamine derivatives, carnosine and pyridoxamine, act on the reactive sugar fragment that forms it rather than on the adduct itself.
100 to 300mg a day is where N(6)-(1-Carboxyethyl)Lysine works.
Source: Advanced glycation end-product (AGE) literature; not a standard supplement
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
N(6)-(1-Carboxyethyl)Lysine is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- marker of cumulative dicarbonyl exposureNarrative review
- formation in heated food through the Maillard reactionIn vitro study
- partial absorption of protein-bound dietary formsNarrative review
Questions people ask about N(6)-(1-Carboxyethyl)Lysine.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
N6-(1-carboxyethyl)lysine forms when methylglyoxal reacts with a lysine side chain on a protein. Pyridoxamine intercepts reactive dicarbonyls and Amadori intermediates before that step, so it lowers formation of this adduct rather than acting on the adduct itself.
Carnosine carries a free imidazole and amine pair that reacts with methylglyoxal, the direct precursor of this lysine adduct. By taking the dicarbonyl out of circulation it competes with protein lysine residues for the same reactive species.
Benfotiamine raises thiamine diphosphate and so activates transketolase, which shunts triose phosphates away from the route that generates methylglyoxal. Less methylglyoxal means less of the carboxyethyl adduct forming on protein lysines.
Thiamine is the vitamin behind the diphosphate cofactor transketolase needs, and it is that enzyme step which drains the triose phosphate pool feeding methylglyoxal formation. Adequate thiamine status therefore sits upstream of how much of this adduct is generated.
Glyoxalase I acts on the hemithioacetal formed spontaneously between glutathione and methylglyoxal, and glyoxalase II regenerates the glutathione. Since methylglyoxal is the dicarbonyl that reacts with lysine residues to give this adduct, glutathione availability sits directly upstream of how much adduct forms. Low glutathione means more free methylglyoxal in the cell.
N-acetylcysteine delivers cysteine, the limiting amino acid for glutathione synthesis by glutamate-cysteine ligase. More glutathione means more substrate for the glyoxalase route that clears methylglyoxal. NAC also carries a free thiol that reacts with dicarbonyls directly, so the connection runs through two routes rather than one.
Human glyoxalase I is a zinc metalloenzyme, with the metal ion coordinating the substrate in the active site. Zinc status is therefore a condition for normal methylglyoxal clearance. This is a cofactor relationship in the strict sense and needs no trial to state.
This adduct is a lysine residue whose epsilon-amino group has been modified by methylglyoxal-derived chemistry. Free lysine carries the same reactive amine and can act as a sacrificial scavenger of dicarbonyls in vitro. Whether supplemental lysine changes adduct formation in a person has not been demonstrated, so this is chemistry rather than an outcome.
Glycine is one of the three amino acids in glutathione and is often limiting alongside cysteine in older adults. It also carries a free amine that can react with reactive carbonyls. Both routes point the same way, upstream of the chemistry that produces this adduct.
Dihydrolipoic acid regenerates glutathione and other thiol antioxidants, keeping the pool that feeds glyoxalase I in its reduced form. Lipoic acid also participates as a cofactor in the dehydrogenase complexes that determine how much triose phosphate accumulates upstream of methylglyoxal. The connection is mechanistic and measured at marker level where measured at all.
Pyridoxal 5-phosphate and its amine relatives carry chemistry that traps reactive carbonyl intermediates, which is the same rationale behind the already-stored pyridoxamine partner. The active B6 form is the coenzyme in scores of transaminations and so sits close to the amino acid chemistry involved. What has been shown is adduct formation in laboratory systems, not a clinical endpoint.
Taurine's free amino group reacts with reactive aldehydes and it is present at high intracellular concentrations, which is why it is described as a carbonyl and hypochlorite scavenger. That places it in the same chemical space as the carnosine partner already stored on this page. The evidence is chemical and cellular rather than clinical.
Quercetin and several related flavonols form covalent adducts with methylglyoxal at their A-ring in laboratory systems, which removes dicarbonyl before it can modify a lysine residue. Whether the amounts reaching tissue after oral intake are enough to matter is not established. Read this as a trapping mechanism demonstrated in vitro.
Resveratrol has been reported to trap methylglyoxal in cell-free systems and to influence glyoxalase I expression in cultured cells. Oral bioavailability is low and heavily conjugated, which limits how far the laboratory result carries. The row is mechanistic and marker-level.
Methylglyoxal arises mainly from spontaneous decomposition of the triose phosphates in glycolysis, and every kinase step in that pathway is magnesium-ATP dependent. Magnesium status therefore sits upstream of how much triose phosphate accumulates. The link is real biochemistry but several steps removed from any measured adduct level.
Glycation adduct formation tracks glucose exposure over time, so anything supporting normal glucose handling sits upstream of it. Chromium is proposed to support normal insulin signalling, though the size of that effect in people with adequate status is contested. This is an indirect and weakly supported link and is flagged as such.
Free cysteine reacts with dicarbonyls through its thiol group and is the rate-limiting precursor for glutathione. Both roles reduce the pool of methylglyoxal available to modify a lysine residue. The chemistry is settled; the clinical consequence is not measured.
Nothing specific on file for N(6)-(1-Carboxyethyl)Lysine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What N(6)-(1-Carboxyethyl)Lysine actually does.
It is what you get when a reactive sugar breakdown product sticks permanently to the lysine in a protein.
The reactive molecule behind it is a side product of ordinary sugar metabolism.
Cells have a dedicated two-enzyme system that mops up the reactive precursor.
It builds up and stays put, which makes it a running record rather than something with a job to do.
Where N(6)-(1-Carboxyethyl)Lysine comes from.
Nothing makes this on purpose for a supplement. It forms by itself when reactive sugar fragments stick to protein, both in the body and in cooked food, and the only version sold is a tiny lab sample used to measure the real thing.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
In the body the starting materials are the epsilon-amino groups of lysine residues in existing proteins and methylglyoxal generated from triose phosphates during glycolysis. In food they are the lysine of a food protein and reducing sugars present in the same matrix.
The dicarbonyl condenses with the lysine amine and the intermediate is reduced to give the stable carboxyethyl adduct. The reaction needs no enzyme and speeds up with heat, time and higher sugar concentration, which is why it happens in a roasting pan and in a long-lived protein alike.
Where the compound is handled as a material it is prepared as an analytical reference standard, made by reacting lysine with methylglyoxal or pyruvate under reducing conditions and purified by preparative chromatography.
Quantification uses stable-isotope-labelled versions of the same molecule as internal standards in liquid chromatography tandem mass spectrometry, since the analyte occurs at low concentrations against a complex background.
The commercial form is a milligram-scale laboratory standard sold for assay calibration. It is not manufactured as a supplement ingredient and does not appear as an intentional formula component.
Getting N(6)-(1-Carboxyethyl)Lysine from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.